Skip to content
Search

Latest Stories

LloydsPharmacy Clinical Homecare awarded overall ‘Good’ rating by CQC

LloydsPharmacy Clinical Homecare has been awarded ‘Good’ rating in all five domains- safe, effective, caring, responsive and well-led by the Care Quality Commission (CQC).

This is recognition of the huge turnaround the service has made in such a short space of time. The Harlow site was inspected in October 2022.


Established in 1975, LloydsPharmacy Clinical Homecare is one of the most experienced providers of clinical homecare, and delivers care to more than 100,000 patients in the comfort of their home, at work, or in the community – ranging from straightforward delivery of medication to specialist nursing for complex conditions. The provider was credited with having ‘significantly improved’ following negative feedback from the regulators last year.

In particular, it was reported that ‘all staff were committed to continually learning and improving services. They had a good understanding of quality improvement methods and the skills to use them, and leaders encouraged innovation and participation in research’.

Inspectors highlighted LloydsPharmacy Clinical Homecare’s Remote Nurse Training service, which is for patients with long-term conditions. ‘The service has enabled patients, through telephone training, to self-inject their ongoing treatments. It has facilitated greater independence for patients and has reduced the risk of transmission of the COVID-19 virus to a patient group that were considered vulnerable.’

With a success rate of 99%, the training programme was rolled out nationally across 13 different biological therapies. The service was a finalist in the Nursing Times Awards 2020 in the category of Managing Long-term Conditions.

Nick Davis, CEO of LloydsPharmacy Clinical Homecare, said: “The CQC’s report reflects how far we have come in the last year. Every single person who is part of the LloydsPharmacy Clinical Homecare team - from our front-line nurses and healthcare assistants to our senior management team, has worked extremely hard to bring the service back to a standard that we can be proud of, however, we will not rest on our laurels as we strive to do even better each day.

“We are all dedicated to our programme of continuous improvement, and the regulator’s feedback is extremely important to us. The inspectors have also provided valuable guidance on where we can make even more progress, and it will help us reach our goal of being rated outstanding in the near future.”

 

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less